EXPLOITING THE DNA DAMAGE RESPONSE (DDR) PATHWAY USING AZD-1775, A WEE1 INHIBITOR, TO SENSITIZE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS TO DIFFERENT ANTINEOPLASTIC DRUGS

被引：0
|
作者：
di Rora, A. Ghelli Luserna [1 ]
Beeharry, N. [3 ]
Imbrogno, E. [1 ]
Ferrari, A. [1 ]
Robustelli, V. [1 ]
Falzacappa, M. V. [2 ]
Ronchini, C. [2 ]
Testoni, N. [1 ]
Baldazzi, C. [1 ]
Papayannidis, C. [1 ]
Abbenante, M. C. [1 ]
Marconi, G. [1 ]
Hittle, J. [3 ]
Cavo, M. [1 ]
Iacobucci, I. [1 ]
Martinelli, G. [1 ]
Yen, T. J. [3 ]
机构：
[1] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[2] European Inst Oncol, Milan, Italy
[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P055
引用
收藏
页码：72 / 72
页数：1
相关论文
共 28 条
  • [1] The Wee1 Inhibitor, MK-1775, Sensitizes Leukemic Cells to Different Antineoplastic Drugs Interfering with DNA Damage Response Pathway
    Di Rora, Andrea Ghelli Luserna
    Iacobucci, Ilaria
    Beeharry, Neil
    Soverini, Simona
    Papayannidis, Cristina
    Martinelli, Giovanni
    Yen, Timothy J.
    BLOOD, 2015, 126 (23)
  • [2] THE INHIBITION OF THE DNA DAMAGE RESPONSE (DDR) USING THE WEE-1 INHIBITOR, MK-1775, SENSITIZES ACUTE LYMPHOBLASTIC LEUKEMIA CELLS TO THE TOXICITY OF DIFFERENT COMPOUNDS
    Di Rora, A. Ghelli Luserna
    Iacobucci, I.
    Beeharry, N.
    Imbrogno, E.
    Papayannidis, C.
    Robustelli, V.
    Ferrari, A.
    Guadagnuolo, V.
    Cavo, M.
    Martinelli, G.
    Yen, T. J.
    HAEMATOLOGICA, 2016, 101 : S68 - S68
  • [3] The WEE1 inhibitor AZD-1775 has synergic activity with trabectedin or lurbinectedin in ovarian cancer cells
    Uboldi, Sarah
    Carrassa, Laura
    Frapolli, Roberta
    Ubezio, Paolo
    Erba, Eugenio
    D'Incalci, Maurizio
    CANCER RESEARCH, 2016, 76
  • [4] A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
    Garcia, Tamara B.
    Snedeker, Jonathan C.
    Baturin, Dmitry
    Gardner, Lori
    Fosmire, Susan P.
    Zhou, Chengjing
    Jordan, Craig T.
    Venkataraman, Sujatha
    Vibhakar, Rajeev
    Porter, Christopher C.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10) : 2058 - 2068
  • [5] Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP-E2F1-DNA damage response pathway axis
    Oku, Yusuke
    Nishiya, Naoyuki
    Tazawa, Takaaki
    Kobayashi, Takaya
    Umezawa, Nanami
    Sugawara, Yasuyo
    Uehara, Yoshimasa
    FEBS OPEN BIO, 2018, 8 (06): : 1001 - 1012
  • [6] Inhibition of DNA damage response pathway using combination of DDR pathway inhibitors and radiation in treatment of acute lymphoblastic leukemia cells
    Katoueezadeh, Maryam
    Pilehvari, Niloofar
    Fatemi, Ahmad
    Hassanshahi, Gholamhossein
    Torabizadeh, Seyedeh Atekeh
    FUTURE ONCOLOGY, 2021, 17 (21) : 2803 - 2816
  • [7] A Comprehensive Study of the Chemosensitizing Effects of AZD-1775, WEE-1 Inhibitor in Combination with DNA Damaging Treatments in the Jurkat Leukemia Cell Model
    Rodriguez, Gabriel Omar
    Carrero, Ricardo
    Diaz-Quinones, Adriana
    Salgado, Iris
    Silva, Walter
    Maldonado, Hector
    FASEB JOURNAL, 2019, 33
  • [8] Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway
    Duan, Yanchao
    Dong, Xin
    Nie, Jing
    Li, Peng
    Lu, Fei
    Ma, Daoxin
    Ji, Chunyan
    ONCOLOGY LETTERS, 2018, 16 (04) : 5473 - 5481
  • [9] THE WEE1 INHIBITION DEEPLY SENSITIZES ACUTE LYMPHOBLASTIC LEUKEMIA CELL LINES AND PRIMARY CELLS TO THE CYTOTOXIC EFFECT OF DIFFERENT ANTINEOPLASTIC COMPOUNDS
    Di Rora, A. Ghelli Luserna
    Iacobucci, I.
    Beeharry, N.
    Papayannidis, C.
    Imbrogno, E.
    Robustelli, V.
    Ferrari, A.
    Guadagnuolo, V.
    Cavo, M.
    Martinelli, G.
    Yen, T. J.
    HAEMATOLOGICA, 2016, 101 : 344 - 344
  • [10] A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
    Zhou, L.
    Zhang, Y.
    Chen, S.
    Kmieciak, M.
    Leng, Y.
    Lin, H.
    Rizzo, K. A.
    Dumur, C. I.
    Ferreira-Gonzalez, A.
    Dai, Y.
    Grant, S.
    LEUKEMIA, 2015, 29 (04) : 807 - 818
123